A recent 125 patient study researching the use of the drugs nivolumab (Opdivo) and ipilimumab (Yervoy) in lieu of standard-of-care chemotherapy (check it out here) has shown great promise. Immunotherapy unlike chemotherapy operates by boosting the immune system to help the body fight off the malignant cells. Dr. Arnaud Scherpereel of University Hospital of Lille in France and lead author of the study wrote, “Our findings suggest that immunotherapy may provide new hope to patients with relapsed mesothelioma,”
Now a new phase III clinical trial is starting (expected to finish in 2021), sponsored by Pharmaceutical giant Bristol Meyers Squibb. Given the recent successes of the new treatment protocol there are expected to be 600 patients from 21 countries participating in the study. Within the United States there are over 17 locations participating in the highly anticipated clinical trial. Some of the participating venues include:
- Moffitt Cancer Center in Tampa, Florida
- WVU Mary Babb Randolph Cancer Center in Morgantown, West Virginia
- University of Chicago Cancer Center
- Abramson Cancer Center in Philadelphia
- Mayo Clinic in Rochester, Minnesota
- Smilow Cancer Hospital in New Haven, Connecticut
- Cleveland Clinic Cancer Center
As the trials get underway we remain hopeful that a new standard in mesothelioma care may be established. To read more about the exciting new trials click here.
The Paul Law Firm advocates for victims of asbestos-related diseases. If you or a loved one is suffering from mesothelioma, call the Paul Law Firm. With over 2.5 billion dollars collected for victims of asbestos exposure, we have the knowledge and the experience to fight for you. We also understand that fighting doesn’t just happen in the courtroom. It also happens in a lab where we are fighting for a cure. Check out the Mesothelioma Research Foundation of America here.
Call us today at 1-855 88 LEGAL (885-3425) or contact us online to discuss your case with one of our experienced mesothelioma lawyers